A phase 4, open-label study to evaluate the short-term innate immune response after administration of a COVID-19 mRNA vaccine (Comirnaty JN.1®) in healthy adults aged 18 to 40 years.

COVID-19

Before, 6 hours after, and 24 hours after the study intervention administration: - Levels of inflammatory biomarkers, such as but not limited to interferon gamma and interleukin-1 alpha and beta (geometric mean, median and quartiles), Before, 6 hours after, and 24 hours after the study intervention administration: - Immune profiling of PBMCs by cell surface protein expression analyses using barcoded antibodies against these marker proteins. - Transcriptomic analyses in PBMCs by single cell RNA sequencing.

Throughout the study duration: - Occurrence of any SAEs related to the vaccine administration as per the judgment of the investigator (percentage of participants).

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Belgium